Invitae 과거 수익 실적

과거 기준 확인 0/6

Invitae의 수입은 연평균 -53.3%의 비율로 감소해 온 반면, Healthcare 산업은 수입이 연평균 5.4%의 비율로 증가했습니다. 매출은 연평균 26.5%의 비율로 증가해 왔습니다.

주요 정보

-53.3%

수익 성장률

-34.1%

EPS 성장률

Healthcare 산업 성장	8.5%
매출 성장률	26.5%
자기자본 수익률	n/a
순이익	-299.1%
최근 수익 업데이트	30 Sep 2023

최근 과거 실적 업데이트

Recent updates

Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely

Dec 20

Invitae maintains 2022 financial guidance as Q2 results beat on top and bottom lines

Aug 09

수익 및 비용 분석

Invitae 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

OTCPK:NVTA.Q 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 23	482	-1,441	361	256
30 Jun 23	494	-800	371	285
31 Mar 23	510	-3,117	389	336
31 Dec 22	516	-3,106	411	402
30 Sep 22	520	-3,212	436	462
30 Jun 22	501	-3,109	484	473
31 Mar 22	481	-451	462	464
31 Dec 21	460	-379	474	416
30 Sep 21	435	-408	599	405
30 Jun 21	389	-313	522	345
31 Mar 21	319	-613	496	284
31 Dec 20	280	-602	438	241
30 Sep 20	245	-445	254	171
30 Jun 20	233	-421	243	180
31 Mar 20	241	-303	230	160
31 Dec 19	217	-242	201	142
30 Sep 19	196	-195	176	107
30 Jun 19	177	-148	151	76
31 Mar 19	161	-131	130	66
31 Dec 18	148	-129	126	63
30 Sep 18	128	-140	119	61
30 Jun 18	109	-136	115	56
31 Mar 18	86	-133	104	52
31 Dec 17	68	-123	91	46
30 Sep 17	52	-108	77	45
30 Jun 17	40	-105	65	45
31 Mar 17	31	-102	57	44
31 Dec 16	25	-100	52	45
30 Sep 16	19	-100	48	44
30 Jun 16	15	-97	45	44
31 Mar 16	11	-97	43	45
31 Dec 15	8	-90	39	43
30 Sep 15	6	-81	35	38
30 Jun 15	4	-71	31	32
31 Mar 15	3	-57	26	26
31 Dec 14	2	-47	21	22
30 Sep 14	1	-40	16	21
30 Jun 14	1	-35	13	20
31 Mar 14	0	-29	10	18
31 Dec 13	0	-25	8	16

양질의 수익: NVTA.Q 은(는) 현재 수익성이 없습니다.

이익 마진 증가: NVTA.Q 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: NVTA.Q 은(는) 수익성이 없으며 지난 5년 동안 연간 53.3% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 NVTA.Q 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: NVTA.Q 은(는) 수익성이 없어 지난 해 수익 성장을 Healthcare 업계( 10.3% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: NVTA.Q 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

Invitae 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2023 earnings: EPS misses analyst expectations

Invitae Corporation to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings: EPS misses analyst expectations

Invitae Corporation to Report Q2, 2023 Results on Aug 08, 2023

First quarter 2023 earnings: EPS misses analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Recent updates

Invitae Launches Unlock Behind the Seizure Program for Pediatric Epilepsy Patients

First Amended Disclosure Statement Approved for Invitae Corporation

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification

Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023

Motion for Asset Sale Filed by Invitae Corporation

Invitae Corporation Filed for Bankruptcy

Invitae Corporation(OTCPK:NVTA) dropped from S&P TMI Index

The New York Stock Exchange to Commence Delisting Proceedings against Invitae

Invitae Corporation May File for Bankruptcy

New minor risk - Market cap size

Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely

Invitae Corporation Announces Board Changes

Invitae Corporation Announces the Retirement of Robert L. Nussbaum as Chief Medical Officer, Effective December 29, 2023

Price target decreased by 11% to US$1.31

Invitae Corporation Appoints Ana J. Schrank as Chief Accounting Officer

Consensus EPS estimates fall by 119%

New major risk - Financial position

Invitae Corporation Reaffirms Earnings Guidance for the Full Year 2023

Price target increased by 30% to US$1.92

Third quarter 2023 earnings: EPS misses analyst expectations

Invitae Corporation to Report Q3, 2023 Results on Nov 08, 2023

Invitae Corporation Announces Findings from the Study to Date on Uncertain Results from Hereditary Disease Genetic Testing

Invitae Corporation Appoints David Sholehvar as Chief Operating Officer, Effective November 13, 2023

Price target decreased by 14% to US$1.58

Invitae Announces Results of Its Collaborative Study on Universal Hereditary Cancer Genetic Testing in All Patients with Breast Cancer in A Rural Population in the Annals of Surgical Oncology

Invitae Corporation Announces Change of Chief Financial Officer, Effective October 2, 2023

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

New major risk - Financial position

Invitae Corporation Announces Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer

Price target decreased by 13% to US$1.70

Consensus EPS estimates fall by 34%

Invitae Corporation Provides Revenue Guidance for the Year 2023

Invitae Corporation Provides Revenue Guidance for the Year 2023

Price target decreased by 8.2% to US$1.87

Second quarter 2023 earnings: EPS misses analyst expectations

Invitae: Revenue Troubles Build

Invitae Corporation to Report Q2, 2023 Results on Aug 08, 2023

Invitae Is Treading In Competitive Waters

Invitae Corporation Announces Executive Changes

Invitae Corporation's (NYSE:NVTA) Prospects Need A Boost To Lift Shares

Invitae Corporation Announces Nine Studies to Be Presented At the 2023 American Society of Clinical Oncology Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology

Invitae Announces CFO Changes

President recently sold US$54k worth of stock

Invitae Corporation Announces It Intends to Appeal the Verdict Delivered by A Jury At the United States District Court

Consensus EPS estimates fall by 19%

First quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 10.0% to US$2.26

Full year 2022 earnings: EPS misses analyst expectations

Invitae Corporation to Report Q4, 2022 Results on Feb 28, 2023

Price target decreased by 7.4% to US$2.51

Invitae Corporation Appoints William H. Osborne to its Board of Directors

Invitae: What Happened At The JP Morgan Health Conference

Invitae guides Q4 revenue above estimates

Director recently sold US$115k worth of stock

Invitae Likely Hasn't Reached The Bottom Yet

Invitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic Research

Invitae Launches Rare Patient Network for Pediatric Patients with Rare Neurodevelopmental Diseases

Consensus forecasts updated

Invitae: This Turnaround Could Be Painful

Invitae Corporation Reiterates Earnings Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Invitae Corporation Reports Asset Impairments for the Third Quarter Ended September 30, 2022

Invitae GAAP EPS of -$1.27 misses by $0.43, revenue of $133.54M beats by $2.16M

Invitae Corporation Study Shows Therapy Informed by Genetic Testing Reduces Seizures in Some Patients with Epilepsy

Invitae Corporation to Report Q3, 2022 Results on Nov 08, 2022

Price target decreased to US$2.71